Jonathan Lee Roth

US Patent:

7399744, Jul 15, 2008

Filed:

May 20, 2004

Appl. No.:

10/851574

Inventors:

Christine Marie Mack - San Diego CA, US
Jonathan David Roth - La Jolla CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/00

US Classification:

514 12

Abstract:

Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.

US Patent:

7723471, May 25, 2010

Filed:

Dec 12, 2005

Appl. No.:

11/301744

Inventors:

Odile Esther Levy - San Diego CA, US
Carolyn M. Jodka - Encinitas CA, US
Soumitra S. Ghosh - San Diego CA, US
David G. Parkes - Del Mar CA, US
Richard A. Pittner - San Diego CA, US
Lawrence J. D'Souza - Del Mar CA, US
John S. Ahn - San Diego CA, US
Kathryn S. Prickett - San Diego CA, US
Jonathan David Roth - San Diego CA, US
Sean H. Adams - Davis CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/00

US Classification:

530324

Abstract:

The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.

US Patent:

8394765, Mar 12, 2013

Filed:

Nov 14, 2007

Appl. No.:

11/940317

Inventors:

Jonathan D. Roth - San Diego CA, US
Christen M. Anderson - Encinitas CA, US
Alain D. Baron - San Diego CA, US

Assignee:

Amylin Pharmaceuticals LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE

International Classification:

A61K 38/00
A61K 38/16
A61K 38/22

US Classification:

514 48, 514 11, 514 58, 514 68, 514 69, 514 213

Abstract:

Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.

US Patent:

8426361, Apr 23, 2013

Filed:

Dec 17, 2009

Appl. No.:

12/640352

Inventors:

Odile Esther Levy - San Diego CA, US
Carolyn M. Jodka - Encinitas CA, US
Soumitra S. Ghosh - San Diego CA, US
David G. Parkes - Del Mar CA, US
Richard A. Pittner - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
John S. Ahn - San Diego CA, US
Kathryn S. Prickett - Foster City CA, US
Jonathan David Roth - San Diego CA, US
Sean H. Adams - Davis CA, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE

International Classification:

A61K 5/22

US Classification:

514 52

Abstract:

The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.

US Patent:

20080176804, Jul 24, 2008

Filed:

Mar 25, 2008

Appl. No.:

12/055147

Inventors:

Christine Marie Mack - San Diego CA, US
Jonathan David Roth - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/16
A61P 3/04

US Classification:

514 12

Abstract:

Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.

US Patent:

20090156474, Jun 18, 2009

Filed:

Nov 1, 2005

Appl. No.:

11/665675

Inventors:

Jonathan D. Roth - San Diego CA, US
Christen M. Anderson - Encinitas CA, US
Alain D. Baron - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/22
A61K 31/718

US Classification:

514 12, 514 60

Abstract:

Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.

US Patent:

20100323955, Dec 23, 2010

Filed:

Nov 14, 2007

Appl. No.:

12/742918

Inventors:

Jonathan David Roth - San Diego CA, US
Alain D. Baron - San Diego CA, US
Christen Anderson - San Diego CA, US

Assignee:

AMYLIN PHARMACEUTICALS, INC. - San Diego CA

International Classification:

A61K 38/22
A61P 3/04

US Classification:

514 49, 514 53

Abstract:

Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.

US Patent:

20120071401, Mar 22, 2012

Filed:

Apr 9, 2010

Appl. No.:

13/263070

Inventors:

Jonathan David Roth - San Diego CA, US
James L. Trevaskis - San Diego CA, US
David G. Parkes - San Diego CA, US

Assignee:

Amylin Pharamaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/17
A61P 5/24
A61P 3/04
A61K 38/38

US Classification:

514 53, 514 102, 514 76

Abstract:

Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.